secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-02-03T23:59:59+00:00
Accession:  0001193125-26-034473
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marvin White retires as Aptevo CEO; COO Jeff Lamothe named successor effective April 1, 2026
--------------------------------------------------------------------------------

- White to become Executive Chair; Lamothe promoted from COO to President and CEO and appointed to Board.
- John Niederhuber transitions from Chairman to Lead Independent Director; Board expands to seven directors.
- Lamothe receives $650K base salary, 60% bonus target, and a one-time $150K cash promotional award.
- Severance Plan modified to align Executive Chair benefits with CEO-level benefits; EVP tier removed.
- Company notes cash runway into 2029, $60M equity line, and clinical progress with mipletamig Phase 1b.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526034473/0001193125-26-034473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526034473/apvo-20260130.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-034473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer